OncoCyte Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Josh Riggs
Chief executive officer
US$514.1k
Total compensation
| CEO salary percentage | 47.1% |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | less than a year |
| Board average tenure | 2.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$17m |
| Mar 31 2023 | n/a | n/a | -US$11m |
| Dec 31 2022 | US$514k | US$242k | -US$19m |
Compensation vs Market: Josh's total compensation ($USD514.11K) is about average for companies of similar size in the German market ($USD418.12K).
Compensation vs Earnings: Insufficient data to compare Josh's compensation with company performance.
CEO
Josh Riggs (40 yo)
less than a year
Tenure
US$514,110
Compensation
Mr. Joshua Riggs, also known as Josh, serves as Director of OncoCyte Corporation since February 28, 2023, serves as its Chief Executive Officer & President since February 24, 2023. He served as Interim Chi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | US$514.11k | no data | |
| Senior Director | 1.1yrs | US$259.74k | 0% € 0 | |
| Chief Science Officer | less than a year | no data | no data | |
| Senior Vice President of R&D and Product Development | no data | no data | no data | |
| Senior Vice President of Business Operations | less than a year | no data | no data | |
| Scientific Advisor | 8yrs | US$328.84k | no data | |
| Secretary | no data | no data | no data | |
| Director of Medical Education | no data | no data | no data |
0.8yrs
Average Tenure
40yo
Average Age
Experienced Management: 7OC0's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | US$514.11k | no data | |
| Lead Independent Director | less than a year | US$17.30k | 0.000040% € 8.6 | |
| Independent Chairman | 8.3yrs | US$125.01k | 0.59% € 127.1k | |
| Independent Director | 14.1yrs | US$118.50k | 0.28% € 59.8k | |
| Member of Scientific & Medical Advisory Board | 2.8yrs | no data | no data | |
| Member of Scientific & Medical Advisory Board | no data | no data | no data | |
| Member of Scientific & Medical Advisory Board | no data | no data | no data | |
| Member of Scientific & Medical Advisory Board | 2.8yrs | no data | no data | |
| Independent Director | 7.8yrs | US$118.00k | 0.037% € 7.8k | |
| Member of Scientific & Medical Advisory Board | 2.8yrs | no data | no data | |
| Member of Scientific & Medical Advisory Board | 2.8yrs | no data | no data | |
| Member of Scientific & Medical Advisory Board | 2.8yrs | no data | no data |
2.8yrs
Average Tenure
64yo
Average Age
Experienced Board: 7OC0's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/22 11:49 |
| End of Day Share Price | 2023/07/25 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
OncoCyte Corporation is covered by 8 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | BTIG |
| Paul Knight | Janney Montgomery Scott LLC |
| null null | KeyBanc Capital Markets Inc. |